Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Mix25 Versus Mix50

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) for at least 6 months~* Have been taking sulfonylureas, biguanide, thiazolidinedione, alpha-glucosidase inhibitor, glinide, or dipeptidyl peptidase IV inhibitor, or any combination of these~* Have a qualifying hemoglobin A1c (HbA1C) value ≥7.0% and ≤11.0% at screening~* Have a body mass index (BMI) ≥18.5 and \<35.0 kilogram per square meter (kg/m²)~* Have given written informed consent to participate in the study in accordance with local regulations and the ethical review board (ERB) governing the study site~Exclusion Criteria:~* Have a diagnosis of type 1 diabetes~* Have had more than 1 episode of severe hypoglycemia within the 6 months before screening~* Have any of the following cardiovascular conditions within 3 months prior to screening: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke)~* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase levels ≥3.0 times the upper limit of the reference range at screening, as determined by the central laboratory~* Have an estimated creatinine clearance (CrCl), Cockcroft-Gault formula \<30 milliliter per minute (mL/min), as determined by the central laboratory at screening~* Have evidence of a significant, active, uncontrolled endocrine or autoimmune abnormality, as judged by the investigator~* Have an active or untreated malignancy or have been in remission from a clinically significant malignancy for \<5 years~* Have any other condition (such as, known drug or alcohol abuse or a psychiatric disorder) that may prevent the participants from following and completing the protocol~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Lispro Mix25 (Type: EXPERIMENTAL): Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
- Insulin Lispro Mix50 (Type: EXPERIMENTAL): Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).